Home ›
Trademark Categories ›
Pharmaceuticals ›
2021 ›
GE ›
GENZIC
Trademark search for:
GENZIC
No active United States Patent and Trademark Office (USPTO) registrations found, based on publicly available USPTO trademark records.
Trademark records may change over time.
For the most up-to-date trademark status, domain availability,
and social handle checks, run a live search.
Check latest trademark, domains & social handles
Live search · Most up-to-date results
USPTO Filing History
Key events recorded for this trademark application
2021-03-17 — Application filed
2021-03-20 — Application filed
2021-06-17 — Application filed
2021-08-20 — Assigned to examiner
2021-08-23 — Approved for pub - principal register
2021-09-08 — Notification of notice of publication e-mailed
2021-09-28 — Published for opposition
2021-09-28 — Official gazette publication confirmation e-mailed
2021-11-23 — Noa e-mailed - sou required from applicant
2022-05-05 — Sou teas extension received
2022-05-05 — Sou extension 1 filed
2022-05-05 — Sou extension 1 granted
2022-05-07 — Notice of approval of extension request e-mailed
2022-11-23 — Sou extension 2 filed
2022-12-26 — Application abandoned
2022-12-27 — Sou extension received with teas petition
2022-12-27 — Notice of revival - e-mailed
2022-12-27 — Petition to revive-granted
2022-12-27 — Teas petition to revive received
2023-02-24 — Case assigned to intent to use paralegal
2023-02-24 — Sou extension 2 granted
2023-02-25 — Notice of approval of extension request e-mailed
2023-06-26 — Application abandoned
2023-06-26 — Application abandoned
2023-06-26 — Final status recorded
Owner Information
Seragon Pharmaceuticals Inc.
Irvine , CA
Seragon Pharmaceuticals Inc.
Irvine , CA
Correspondent
Seragon Pharmaceuticals Inc. 400 SPECTRUM CENTER DR., STE. 1600 IRVINE, CA 92618 UNITED STATES
Filing Details
Filing Date:
2021-03-17
Status Date:
2023-06-26
Disclaimer: This page is informational only and does not constitute legal advice.
Trademark availability depends on jurisdiction, usage, and legal interpretation.